Company: ABBV
Filing Date: 2025-08-04
Form Type: 10-Q
Source: 0001551152-25-000040
Chunk: 54

Company: AbbVie Inc.
Filing Date: 2025-08-04
Form: 10-Q
Item: Part I, Item 1
Chunk 54
---
 2024. The CODM uses net earnings as its principal measure of segment profit or loss to compare past financial performance with current performance and analyze underlying business performance and trends. The CODM does not use segment assets to make decisions regarding resources; therefore, the total asset disclosure has not been included.The following table details AbbVie’s worldwide net revenues:Three months endedJune 30,Six months endedJune 30,(in millions)2025202420252024ImmunologySkyriziUnited States$3,843 $2,340 $6,762 $3,996 International580 387 1,086 739 Total$4,423 $2,727 $7,848 $4,735 RinvoqUnited States$1,452 $1,017 $2,672 $1,742 International576 413 1,074 781 Total$2,028 $1,430 $3,746 $2,523 HumiraUnited States$802 $2,360 $1,546 $4,131 International378 454 755 953 Total$1,180 $2,814 $2,301 $5,084 NeuroscienceVraylarUnited States$898 $773 $1,661 $1,465 International2 1 4 3 Total$900 $774 $1,665 $1,468 Botox TherapeuticUnited States$775 $669 $1,498 $1,280 International153 145 296 282 Total$928 $814 $1,794 $1,562 UbrelvyUnited States$330 $227 $563 $424 International8 4 15 10 Total$338 $231 $578 $434 QuliptaUnited States$237 $146 $409 $274 International30 4 51 7 Total$267 $150 $460 $281 VyalevUnited States$22 $— $28 $— International76 18 133 27 Total$98 $18 $161 $27 DuodopaUnited States$20 $23 $40 $48 International77 90 153 180 Total$97